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ABSTRACT 
Cancer is the second-largest cause of death in the U.S. and approximately two-thirds of all cancer patients 
will receive radiation therapy with the majority of the radiation treatments performed using x-rays 
produced by electron linacs. Charged particle beam radiation therapy, both protons and light ions, 
however, offers advantageous physical-dose distributions over conventional photon radiotherapy, and, for 
particles heavier than protons, a significant biological advantage. Despite recognition of potential 
advantages, there is almost no research activity in this field in the U.S. due to the lack of clinical 
accelerator facilities offering light ion therapy in the States. In January, 2013, a joint DOE/NCI workshop 
was convened to address the challenges of light ion therapy [1], inviting more than 60 experts from 
diverse fields related to radiation therapy. This paper reports on the conclusions of the workshop, then 
translates the clinical requirements into accelerator and beam-delivery technical specifications.  A 
comparison of available or feasible accelerator technologies is compared, including a new concept for a 
compact, CW, and variable energy light ion accelerator currently under development.  This new light ion 
accelerator is based on advances in nonscaling Fixed-Field Alternating gradient (FFAG) accelerator 
design. The new design concepts combine isochronous orbits with long (up to 4m) straight sections in a 
compact racetrack format allowing inner circulating orbits to be energy selected for low-loss, CW 
extraction, effectively eliminating the high-loss energy degrader in conventional CW cyclotron designs. 
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1. INTRODUCTION 
 
Cancer is the second-largest cause of death in the U.S.  About half of all cancer patients receive definitive 
radiation therapy either as their primary treatment or in combination with chemotherapy or surgery; 
overall approximately two-thirds of all cancer patients will receive radiation therapy at some point during 
their illness.  Radiation therapy is currently a very dynamic research field driven by new technology 
developments. The majority of radiation treatments are still performed with linacs that generate energetic 
electron beams and x-rays. However particle beam therapy using proton and carbon ion beams has rapidly 
evolved into a new frontier in cancer therapy.  
 
Charged particle beam radiation therapy with protons and ions offers advantageous physical-dose 
distributions over photon radiotherapy, and, for particles heavier than protons, a potential biological 
advantage. Despite recognition of reported advantages, there is almost no research activity in this field in 
the U.S. due to the lack of clinical accelerator facilities offering carbon and other light ion therapy in the 
U.S.   Recognizing this problem, the NCI jointly with DOE recently organized a workshop on ion beam 
therapy where more than 60 experts from diverse fields related to radiation therapy were asked to define 
research and technical needs for advancing charged particle therapy. The detailed final report of this 
workshop [1] serves as a baseline resource for planning a next-generation Particle Beam Therapy 
Research and Development Center and is utilized as the basis for the clinical and technical specifications 
outlined in this paper. The workshop was followed by a NCI grant to fund planning efforts for research 
centers in conjunction with independent commitments to construct Particle Beam Radiation Therapy 
facilities in the U.S.  Scientific and technology consortia involving leading institutions experienced in 
particle therapy and accelerator technology have formed to develop the next generation of ion beam 
accelerators and therapy technologies. At the workshop a list of clinical requirements were compiled in 
order to address outstanding treatment issues and research needs to be incorporated into the planning 
effort and next stage towards a facility.  These include reducing range uncertainties, managing tumor and 
organ motion, proximity of tumors to critical normal structures, matching the biological effectiveness of 
different ion beams to specific tumor characteristics, clinical trials and protocols for hypfractionation and 
multi-ion treatments, in addition to basic radiobiology research.  The clinical requirements identified in 
the workshop for a National Particle Beam Research Center and subsequently extracted from the report 
are summarized in Table I.  
 
The cost and footprint of an ion therapy facility are considered the primary economical obstacles to 
widespread adoption of this promising therapy. New accelerator technologies must address capital costs in 
the form of compact accelerators and beam delivery systems; the latter especially in ion gantries.  
Compact therapy accelerators to date are represented by AVF cyclotrons with energy degraders.  Higher 
fixed-energy ion cyclotrons have not been adopted over the more costly synchrotron due to increased 
shielding and radio-activation issues.  Although linacs can produce rapid energy changes combined with 
high dose deposition rates, they remain the most costly of the accelerator systems.  The solution proposed 
here is a new type of FFAG accelerator which combines advantageous features of the synchrotron and 
cyclotron: strong focusing machine tunes with low-loss variable-energy extraction and a CW beam 
format, respectively. 
 
2.  SPECIFICATIONS FOR A LIGHT ION FACILITY 
 
Progress on the issues and requirements identified in the workshop necessarily rely on technical 
innovation in accelerator, beam delivery, and imaging systems.  Some goals such as reducing range 
uncertainties, accurately differentiating between the tumor and normal tissues to enable precision dose 
delivery while minimizing the radiation dose to normal tissue can only be realized through incorporating 
particle-beam imaging and range measurements into the treatment planning –combined with real-time 
dose verification during treatment.  Imaging, particularly pCT, however, are not simple add-ons – they 
must be integrated into the accelerator and beam delivery at the conceptual design stage.  Switching 
rapidly between ion species is an integral part of a state-of-the-art facility.  
 
 
Table I. Ion Therapy Facility clinical requirements per NCI/DOE report [1]. 
 
 
 
2.1 Accelerator and Beam Delivery Performance Specifications 
 
Requirements for high dose rates and effective motion management put challenging requirements on 
beam scanning rates and energy step times.  To maintain safety standards with high dose rates next-
generation machines will have to rely on fast real-time imaging and improved monitoring and controls 
technology. Preparation for a final end-to-end facility concept must assure compatible performance at all 
levels of every system from multi-ion sources through gantry beam delivery. Not only must next-
Multi-ion capability p, He, Li, B, C (O and Ne also desirable) 
Fast switching between ion species (≤1 sec)  
Energy range 60 MeV/nucleon to 430 MeV/nucleon 
Depths up to 30 cm for carbon ions 
Field size At least 20 x 20 cm2 (optimally up to 40 x 40 cm2) 
Real-time imaging (radiography and CT):  
For tumor position verification and motion 
control 
For patient sizes up to 60 cm in depth. 
 
Dose delivery rates:  
Minimum requirement 
Hypofractionation treatments in under 1 minute, 
(ideally in one breath hold for motion control) 
 
20 Gy/minute 
up to 5-8 Gy/8 sec (breath-hold) for a cubic liter 
 
Pencil beam scanning: 
Fast treatment for a large variety of tumor sizes 
and shapes.  Two extremes are considered:  30 
cm x 30 cm tumor single layer in depth and a 
cubic volume 
Transverse scanning rate of 1-10 cm/msec 
Energy step time of 10-100 msec 
(These are present state-of-the-art for NC and SC 
magnetic components) 
Transverse beam size: 
selectable, with stable, Gaussian profiles. 
3 mm to 10 mm FWHM 
Energy step size Protons:  2 MeV (~0.25 cm in range) 
Carbon: 2 MeV/nucleon (~0.1 cm in range) 
Lateral targeting accuracy at the Bragg peak Protons: ±0.5 mm 
Carbon: ±0.2 mm 
Dose accuracy/fraction   2.5% monitored at ≥40 kHz during dose 
deposition 
generation accelerators, beam-delivery, and imaging technologies meet exceptionally demanding clinical 
requirements listed here, civil construction and operational costs must be reduced significantly from 
current facilities without compromising expanded capability.  
 
Many requirements listed in Table I entail innovative integration of diverse and advanced delivery and 
diagnostic development, but all systems must be supported by the accelerator beam format and delivery 
modes. To better understand the intersection of the accelerator and beam delivery with the clinical, the 
requirements in Table 1 are translated into actual dose deposition rates expressed in terms of machine and 
delivery performance parameters.  These are presented in Table II and are then used for design, selection, 
and comparison purposes between accelerator systems. 
 
In Table II, two different dose deposition criteria were applied, based on minute and second timescales, 
and extrapolated into estimates of beam intensity. For example, the technical specification for a proton 
Computed Tomography (pCT) imaging system is only 106-107 particle/sec and preferably CW due to 
intrinsic individual-particle tracking and reconstruction limitations.  This is a very different condition and 
demand on the accelerator, delivery, and controls as compared with an escalated dose rate of 1012 p/sec for 
target motion management.  Combining the two results represents an unprecedented, but achievable, 
dynamical range for accelerator operation.  Short high dose rates on second timescales remain the most 
demanding environment for accelerator performance. (It should be noted that longer timescales will likely 
be used in practice; i.e. the breath-hold rates, but the intent here is to define upper limits on accelerator 
performance which could be envisioned.) 
 
Table II. Dose delivery rates expressed in terms of accelerator performance for two different 
timescales (minutes and seconds or a breath hold period of 5-8 sec) for different dose regimes: 
standard fractions, hypofractions, and radiobiology research.  Assumes average of 109 p/cm2 for a 1 
Gy dose.  For carbon this should be divided by the RBE ratio which is on average, ~3.  These two 
timescales are useful for implementation of higher-dose protocols. 
 
Dose Delivery Rate 30 x 30 cm2 field 
 single layer/energy 
sweep step size 5 mm 
10 x 10 x 10 cm3 field   
      40 layers/energy steps 
sweep step size 5 mm 
Ions: (charge to mass ½) minimum set 
Additional ions - optimal 
H2+,4He2+,6Li3+,10B105+,12C6+ 
14N7+,16O8+,20Ne10+ 
  
Imaging: 1 to 10 MHz data systems 106-107 p/sec 106-107 p/sec 
Normal Fraction: 1-2 Gy/fraction 
 1 Gy/min 
 1 Gy/sec 
 
1/60 x 1012 p/sec 
1 x 1012 p/sec 
 
4/60 x 1012 p/sec 
4 x 1012 p/sec* 
Hypofraction Regime: 5-8 Gy/fraction 
5-8 Gy/min 
5-8 Gy/sec 
5-8 Gy/breathhold 
 
(5-8)/60 x 1012 p/sec 
5-8 x 1012 p/sec 
1 x 1012 p/sec 
 
(5-8)/60 x 1012 p/sec 
2-3 x 1013 p/sec* 
4 x 1012 p/sec* 
Radiobiology: up to 20 Gy/fraction 
20 Gy/min 
20 Gy/sec 
20 Gy/breathhold 
 
(2)/60 x 1013 p/sec 
2 x 1013 p/sec 
2-4 x 1012 p/sec 
 
8/60 x 1013 p/sec 
8 x 1013 p/sec* 
1-2 x 1013 p/sec* 
 
3. ACCELERATOR COMPARISONS 
 
Current ion therapy facilities use slow-extracting synchrotrons, however, further developments are needed 
to reduce cost and footprint and overcome limitations on intensity and energy modulation.  New, rapid-
cycling synchrotrons may overcome the limitations of slow-extracting synchrotrons but retain a very large 
footprint and require new technical limits on controls technology and dose delivery. The ultra-short beam 
spill (33 and 16 millisec vs 1 sec) would eliminate much of the existing spill uniformity controls, 
diagnostics, and scanning and gating technologies. Proposed studies to explore the biology of 
hypofractionation with intense, ultra-short dose depositions (1 – 8 sec timescales) are not possible with a 
conventional synchrotron.  Although many proton facilities use cyclotrons, scaling cyclotrons to the 
higher energies required for ion facilities presents many challenges particularly in degrader-based beam 
delivery. The cyclinac is an interesting combination of technologies however the upstream injector 
cyclotron is not well matched to the higher-energy linac with high beam losses projected. It has recently 
evolved into a “bent” linac layout with 180 degree achromatic arc to reduce the linear footprint. However, 
the single-pass linac structure remains the most costly of the ion accelerators.  A relatively new approach, 
a CW-beam non-scaling FFAG accelerator combines many of the strengths of synchrotrons and 
cyclotrons, has recently matured to a prototyping and implementation stage, and is the solution promoted 
here.  An assessment of accelerator options in terms of their capability to meet clinical requirements is 
summarized in Table III. 
 
 
Table III. Accelerator options and an assessment of performance for ion therapy 
 
 
 
 
Accelerator Type Size Max Dose Rate 
/liter 
Energy Modulation 
Var/   Machine     Beam Delivery 
Fixed   Time         NC          SC 
Scanning 
Transverse (T) 
Longitudinal (L) 
SC Synchrotron 20-40 m  
(diam) 
5 Gy/min 
0.2 Gy/sec 
V 1 ms – 
2 sec 
10 ms 100 ms T + L 
in acc cycle 
RC Synchrotron 60 m 
(circum) 
~x Cycle factor 
1.3-20 Gy/min 
V 1 – 66 
ms 
10 ms 100 ms L TBD 
T cyc to cyc 
Compact Proton 
Synchrotron 
 
Hitachi 
5 m 
(diam) 
 
8 m 
 
0.075 Gy/min 
0.0025 Gy/sec 
 
0.75 Gy/min 
0.025 Gy/sec 
V 
 
 
V 
 
1 ms -2 
sec 
 
10 ms 
 
100 ms 
T + L 
T + L 
In acc cycle 
in cycle 
Linac/Cyclinac 40 -80m Any rate V 1 ms 10 ms 100 ms Any 
Cyclotron 6.3 m 
(diam) 
5 Gy/min 
0.08 Gy/sec 
F 
 
1 ms 10 ms 100 ms T then L 
FFAG 4m x 6m 
racetrack 
Any rate V 50 µsec  10 ms 100 ms Any 
4. ACCELERATOR APPROACH 
 
FFAG (Fixed-Field Alternating-Gradient) accelerators are a class of accelerators that merge the best 
features of cyclotrons and synchrotrons. They can deliver continuous beam in combination with low loss 
operation and variable energy, specifically at the high energies required for carbon therapy and the high 
intensities required for radiobiology. The FFAG successfully blends the fixed fields of cyclotrons with the 
strong focusing fields of synchrotrons to achieve the isochronous orbits of the cyclotron (at higher 
energies than the cyclotron), and the strong, constant tune of the synchrotron in an aggressively compact 
footprint.  Isochronous orbits allow use of a fixed-frequency Radio-Frequency (RF) system enabling 
continuous beam, and maximum flexibility in real-time imaging and pencil-beam scanning - all at the 
high energies required for imaging and ion therapy.  Constant tune further not only minimizes 
acceleration losses, it facilitates the insertion of long straight sections thereby promoting efficient, low-
loss extraction as evidenced in synchrotron operation. Straight sections also allow for fast switching, even 
multi-ion injection and variable energy extraction. These FFAG design features appear unusually well 
matched to the requirements of a next-generation ion beam therapy system and are potentially 
economical, with costs comparable to the cyclotron. No FFAGs have yet been built specifically for 
radiation therapy but comparable operating FFAG (scaling) systems exist in Japan. We are presently 
designing and evaluating a a new design, presented here, of an ultra-compact, variable-energy, non-
scaling, continuous wave (CW) FFAG for ion therapy. 
 
The capabilities of FFAG accelerator designs meet specifications for the requirements for future ion beam 
therapy systems as identified in Tables 1 and 2. These requirements include the ability to deliver multiple 
light ion types (protons, deuterons, helium, carbon, possibly up to neon), short deposition times with 
image-guidance and real-time measurements of patient parameters, rapid beam scanning and energy 
modulation, with energies up to 430 MeV/nucleon, and with all components optimized for effective and 
safe operation. With multiport injection and extraction capability both imaging and treatment beams can 
be accelerated in the FFAG with appropriate energy and range requirements and rapid ion species 
switching or interleaving times (<sec).  On board imaging beams would initiate at the accelerator and be 
transported through the beam delivery system or through a dedicated multiport delivery system for 
imaging, achieving the ultra-low currents required for imaging without difficult measures on the main 
treatment-beam accelerating systems. 
4.1 A CW, Variable-energy FFAG Accelerator for Ion Therapy 
 
We have designed a 70 - 430 MeV/nucleon FFAG in a racetrack layout that supports two opposing long 
straight sections for rapid acceleration and efficient injection and extraction, in a highly compact footprint 
(~11m x 15m for normal conducting and ~6m x 10m for superconducting arcs). One or more injectors can 
be utilized for multi-ion injection or rapid switching.  This FFAG can accelerate ions with a charge to 
mass ratio of 1:2 (e.g. H2, He, B, Li, C) and is ideal for radiation therapy. The long synchrotron-like 
straight sections permit rapid variable energy extraction on the timescale of milliseconds eliminating the 
need for a substantive beam degrader. High-gradient synchrotron-like RF modules can also be exploited 
in the opposing straight for rapid, low-loss acceleration – this is to be compared to the lower-gradient Dee 
cavities used in compact cyclotrons. Figures 1 show basic concepts and dimensions including a footprint 
comparison with the rapid cycling synchrotron design for 430 MeV/nucleon.  The energy of 330 
MeV/nucleon was chosen to support predominately He therapy @250 MeV/nucleon with particle-beam 
imaging which requires 330 MeV/nucleon.  Lower energy carbon ion therapy can also be applied with 
this accelerator.   
 
 
 
 
 
Figure 1.  Comparison of a 300 MeV/nucleon ion FFAG accelerator with the 430 MeV/nucleon 
Rapid Cycling racetrack synchrotron (~30 x 60 m footprint). 
 
Preliminary studies indicate strong tune stability over the acceleration range as shown in Figure 2. Initial 
isochronous orbits are at ~ a percent level, with ongoing work on refining and smoothing orbits to achieve 
the required stability during acceleration.  However the strong focusing produces a parabolic time of 
flight curve which allows acceleration via the serpentine channel and lower isochronous tolerances on 
orbital path lengths as a function of energy. 
 
 
 
Figure 2.  Strong focusing machine tune over the 70-330 MeV/nucleon acceleration range. 
 
 
 
 
5. SUMMARY 
 
Our analysis shows that a non-scaling, CW FFAG exhibits great potential as a highly compact and 
economically viable alternative to synchrotrons, cyclotrons, linear accelerators and other linac formats for 
next-generation ion beam radiation therapy. The fixed fields and fixed RF simplify operations compared 
to synchrotrons which must ramp fields in coordination with swept-frequency RF. The injector could be a 
lower-energy FFAG or cyclotron which,  in principle, can serve as a standalone accelerator for certain 
treatments (e.g. ocular melanoma) or could be used to accelerate protons to ~300 MeV for proton 
Computed Tomography (pCT).  This machine is currently under international development and 
will be ready for either a National Particle Beam Radiation Center or private ion therapy 
facilities on approximately a 5-year timescale. 
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